Company profile
Ocular Therapeutix, Inc.
NASDAQ: OCUL · Healthcare · Biotechnology
PublicHQ Bedford, MACIK 0001393434Reports USD
#432 of 1,422 Healthcare companies by revenue28th-percentile growth
EA Score
62CFH 51DQ 86GM 39SS 73
v0.1 · 65/100 weight · provisional
↑ filing timeliness, Altman-Z · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$52.0M
Rev growth YoY (TTM)
-12.8%
Net income (FY)
-$265.9M
Employees
325
as of 2026-08-09
Market cap
$2.0B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$52.0M$52.0M2025
Net income-$265.9M-$265.9M2025
Operating income-$270.0M-$270.0M2025
Total assets$808.1M$808.1M2025
Liabilities$153.7M$153.7M2025
Equity$654.3M$654.3M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
Collaboration revenue0%
By geography
Not disclosed.
The read
What is Ocular Therapeutix, Inc.’s revenue?
Ocular Therapeutix, Inc. booked $52.0M in FY2025 revenue, contracting 18% year over year — slower than 72% of Healthcare companies we track, at a -511.9% net margin.
Peers · Healthcare
1CM Inc.70BONE Bio Corp.——Vext Science, Inc.64CNeptune Wellness Solutions Inc.——LENSAR Inc55CCipher Pharmaceuticals Inc.84B+Key facts
CEOPravin U. Dugel
SectorHealthcare
IndustryBiotechnology
HeadquartersBedford, MA
ExchangeNASDAQ: OCUL
Employees325
IPO date2014-07-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.